Physician profile
Jaime Lecomte
NPI 1740858778
$15,057.47
in general payments reported to CMS, 2019-2025
24 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.84 · 2022: $3,669 · 2023: $9,425 · 2024: $1,703 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,400 · Food and Beverage: $4,063 · Travel and Lodging: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,400.00 |
| Food and Beverage | $4,062.52 |
| Travel and Lodging | $1,867.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $7,210.06 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $1,688.78 | 2022-2024 | Senza |
| Vertos Medical, INC. | $1,684.47 | 2022-2024 | Mild Device Kit |
| Boston Scientific Corporation | $1,021.00 | 2022-2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Spinal Simplicity, LLC | $1,011.71 | 2023 | Ha Minuteman G3-R |
| Abbvie INC. | $638.92 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $490.40 | 2021-2024 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $288.62 | 2024 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.26 | 2023-2024 | Relistor |
| Pfizer INC. | $204.86 | 2023-2024 | |
| Abbott Laboratories | $146.72 | 2023-2024 | Proclaim, Eterna |
| Scilex Pharmaceuticals INC. | $139.89 | 2021-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $62.54 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $38.64 | 2024 | Rexulti |
| Allergan, INC. | $29.58 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $26.63 | 2021 | |
| Lundbeck LLC | $23.04 | 2024 | Vyepti |
| Kowa Pharmaceuticals America, INC. | $21.39 | 2023 | Seglentis |
| Globus Medical, INC. | $21.34 | 2025 | Senza |
| Mml US, INC. | $16.19 | 2023 | Reactiv8 |
| Ironshore Pharmaceuticals INC. | $15.04 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.73 | 2024 | Invega Sustenna |
| Bioventus LLC | $13.52 | 2023 | Durolane |
| Lilly USA, LLC | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Lecomte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.